LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases

• LPX-TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin(Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and multiple sclerosis with the intent to expand into additional therapeutic indications. • In healthy adults, LPX-TI641 was orally bioavailable and was safe and well tolerated up to the highest tested doses.

The release as fetched from its publisher. lapix.com ↗